Alex F Herrera
Overview
Explore the profile of Alex F Herrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
133
Citations
3501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuruvilla J, Armand P, Herrera A, Ribrag V, Thieblemont C, von Tresckow B, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40043848
Background: The safety and efficacy of allogeneic stem cell transplantation (allo-SCT) following anti-programmed cell death protein 1 (PD-1) therapy in participants with hematologic malignances is of high clinical interest. Objective:...
2.
Chavez J, Dickinson M, Munoz J, Ulrickson M, Thieblemont C, Oluwole O, et al.
Blood
. 2025 Feb;
PMID: 39938019
ZUMA-12 is a multicenter phase 2 study that evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, as part of first-line treatment in patients with high-risk...
3.
Rhee J, Pillai R, Chen S, Bosworth A, Oganesyan A, Atencio L, et al.
JACC CardioOncol
. 2025 Feb;
7(1):20-33.
PMID: 39896122
Background: Patients with lymphoma are at high risk for developing heart failure (HF) after autologous hematopoietic cell transplantation (HCT). More accurate risk determination pre-HCT may facilitate screening and prevention of...
4.
Herrera A, LeBlanc M, Friedberg J
N Engl J Med
. 2025 Jan;
392(1):102.
PMID: 39752312
No abstract available.
5.
Nze C, Herrera A
Blood Adv
. 2024 Dec;
9(4):774-782.
PMID: 39631075
New lymphoma treatments, including chimeric antigen receptor T cells, bispecific antibodies, and immune checkpoint inhibitors, have significantly improved patient outcomes. Despite these therapeutic advances, only 2% to 3% of adult...
6.
Lurain K, El Zarif T, Ramaswami R, Nassar A, Adib E, Abdel-Wahab N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
24(12):873.
PMID: 39603773
No abstract available.
7.
Herrera A, LeBlanc M, Castellino S, Li H, Rutherford S, Evens A, et al.
N Engl J Med
. 2024 Oct;
391(15):1379-1389.
PMID: 39413375
Background: Incorporating brentuximab vedotin into the treatment of advanced-stage classic Hodgkin's lymphoma improves outcomes in adult and pediatric patients. However, brentuximab vedotin increases the toxic effects of treatment in adults,...
8.
Mercadal S, Ahn K, Allbee-Johnson M, Ganguly S, Ramakrishnan Geethakumari P, Hong S, et al.
Haematologica
. 2024 Sep;
110(1):218-221.
PMID: 39234871
No abstract available.
9.
Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, et al.
Blood Adv
. 2024 Aug;
8(21):5458-5466.
PMID: 39213424
There are limited data assessing the risk scores for primary treatment failure (PTF) in patients with classical Hodgkin lymphoma (cHL; PTF-cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). ECLIPSE (Evaluation of...
10.
Herrera A, Zain J, Savage K, Feldman T, Brammer J, Chen L, et al.
Lancet Haematol
. 2024 Jul;
11(9):e671-e681.
PMID: 39067464
Background: CD30 expression is universal in anaplastic large-cell lymphoma and is expressed in some other peripheral T-cell lymphoma subtypes. Incorporation of brentuximab vedotin into initial therapy for people with CD30-positive...